Popular GLP-1 weight-loss drugs like Ozempic and Zepbound can help reduce a woman’s risk for as many as 14 cancers associated with obesity, a new study says.This article was originally published on MedicalXpress.com
Combined body mass index (BMI)-body surface area (BSA) obesity is associated with an increased risk for post-kidney transplant (KT) adverse outcomes, according to a study published online May 21 in Transplantation Direct.This article was originally […]
Public health experts are urging the new Albanese Government to prioritize tackling obesity, with new research showing widespread public support for the implementation of strong measures to curb the consumption of sugary and sweetened beverages.This […]
Losing weight via lifestyle adjustments can deliver significant long-term health benefits, without the need for surgery or anti-obesity drugs. Alongside preventing diabetes, it can help ward off chronic conditions including arterial and pulmonary diseases as […]
A research group has identified the so-called PNOC/NPY nerve cells in the brains of mice. When activated, these cells increase food intake and lead to obesity. Interestingly, these nerve cells are also present in the […]
As Australia faces a turning point in obesity management, researchers from Monash University have contributed new insights into the rapidly evolving use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) such as Ozempic in the Australian […]
Researchers have found that central body fat, especially around the abdomen, is more strongly linked to psoriasis risk than total body fat, particularly in women. This link between central fat and psoriasis remained consistent regardless […]
Scientists at the Mind, Brain, and Behavior Research Center at the University of Granada (CIMCYC) have revealed how, when faced with highly appetizing and unhealthy food stimuli, many overweight people or those prone to binge […]
Semaglutide belongs to a group of drugs called GLP-1R agonists and has been shown to effectively reduce food intake and body weight. The drug is already well established as part of the treatment for obesity […]
A federal deadline ending sale of off-brand weight-loss and diabetes medications is now in effect, cutting off access to drugs many patients count on.This article was originally published on MedicalXpress.com
© 2025 SimplyWell.ca